Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Rinvoq (upadacitinib) and Humira (adalimumab) are both medications used to treat inflammatory conditions like rheumatoid arthritis (RA) and Crohn's disease (CD). However, they belong to different medication classes. Rinvoq is a Janus kinase (JAK) inhibitor, while Humira is a biologic disease-modifying antirheumatic drug (DMARD) that blocks tumor necrosis factor (TNF). Rinvoq is taken orally, usually once a day, and is available as an extended-release tablet and an oral solution. In contrast, Humira is injected under the skin, typically every other week, and is available as a prefilled injection pen. Common side effects of Rinvoq include a higher risk of infections and acne, while Humira can cause injection-site reactions and upper respiratory infections. Both medications can increase the risk of serious infections, but they have different interactions and precautions, such as avoiding grapefruit with Rinvoq and caution with live vaccines with Humira.
Rinvoq (upadacitinib)
Humira (adalimumab)
Rinvoq (upadacitinib)
Humira (adalimumab)
Summary of Rinvoq vs. Humira
Summary for JAK inhibitor
Prescription only
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.
Summary for TNF blocker
Prescription only
Humira (adalimumab) is an injection used to treat many different autoimmune conditions like rheumatoid arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. As a TNF blocker, the medication works by blocking a protein that causes inflammation in your body. It's given as a shot under the skin once every 1 to 2 weeks, depending on your condition. Humira (adalimumab) doesn't have a true generic, but there are several similar versions called biosimilars. Common side effects include infections, injection site reactions, and headache.
Indications of Rinvoq vs. Humira
Indications for
Moderate-to-severe inflammatory conditions in which other treatments haven't worked:
•Urinary tract infection (UTI) or bladder infection (8%)
Note: The side effects listed above were reported by adults with rheumatoid arthritis and are similar to those seen in people using Humira (adalimumab) for other conditions.
Warnings of Rinvoq vs. Humira
Common Side Effects for
•Serious infections
•Possible higher risk of death for people with rheumatoid arthritis
•Risk of cancer
•Possible risk of heart attack, stroke, and other blood clots